Valneva SE
PAR:VLA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Hangzhou Hikvision Digital Technology Co Ltd
SZSE:002415
|
CN |
Valneva SE
Total Equity
Valneva SE
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Valneva SE
PAR:VLA
|
Total Equity
€150.5m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
14%
|
CAGR 10-Years
0%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Total Equity
€52.5m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
11%
|
CAGR 10-Years
-2%
|
|
|
Inventiva SA
PAR:IVA
|
Total Equity
-€8.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Total Equity
$86.2m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-2%
|
|
|
Abivax SA
PAR:ABVX
|
Total Equity
-€48m
|
CAGR 3-Years
-291%
|
CAGR 5-Years
-68%
|
CAGR 10-Years
N/A
|
|
|
Sensorion SA
PAR:ALSEN
|
Total Equity
€44.5m
|
CAGR 3-Years
27%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
13%
|
|
Valneva SE
Glance View
Valneva SE is a biotech company. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 722 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
See Also
What is Valneva SE's Total Equity?
Total Equity
150.5m
EUR
Based on the financial report for Dec 31, 2025, Valneva SE's Total Equity amounts to 150.5m EUR.
What is Valneva SE's Total Equity growth rate?
Total Equity CAGR 10Y
0%
Over the last year, the Total Equity growth was -17%. The average annual Total Equity growth rates for Valneva SE have been -12% over the past three years , 14% over the past five years .
